CLINICAL TRIALS PROFILE FOR KRAZATI
✉ Email this page to a colleague
All Clinical Trials for krazati
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05840510 ↗ | Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19) | Not yet recruiting | Aadi Bioscience, Inc. | Phase 1/Phase 2 | 2023-05-31 | This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation. |
NCT05840510 ↗ | Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19) | Not yet recruiting | Mirati Therapeutics Inc. | Phase 1/Phase 2 | 2023-05-31 | This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation. |
NCT05853575 ↗ | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | Recruiting | Mirati Therapeutics Inc. | Phase 2 | 2023-04-05 | This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation. |
NCT06026410 ↗ | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Recruiting | Mirati Therapeutics Inc. | Phase 1 | 2023-10-18 | This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors. |
NCT06026410 ↗ | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Recruiting | Kura Oncology, Inc. | Phase 1 | 2023-10-18 | This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for krazati
Condition Name
Clinical Trial Locations for krazati
Trials by Country
Clinical Trial Progress for krazati
Clinical Trial Phase
Clinical Trial Sponsors for krazati
Sponsor Name